These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

585 related items for PubMed ID: 23455361

  • 1. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.
    Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N.
    Eur Heart J; 2014 Mar; 35(11):716-24. PubMed ID: 23455361
    [Abstract] [Full Text] [Related]

  • 2. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY, Li QQ, Zhang C, Zhang HS, Gu H.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr 24; 48(4):315-322. PubMed ID: 32370483
    [Abstract] [Full Text] [Related]

  • 3. Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL Registry).
    Barst RJ, Ivy DD, Foreman AJ, McGoon MD, Rosenzweig EB.
    Am J Cardiol; 2014 Jan 01; 113(1):147-55. PubMed ID: 24176071
    [Abstract] [Full Text] [Related]

  • 4. Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts.
    Vijarnsorn C, Durongpisitkul K, Chungsomprasong P, Bositthipichet D, Ketsara S, Titaram Y, Chanthong P, Kanjanauthai S, Soongswang J.
    PLoS One; 2018 Jan 01; 13(4):e0195092. PubMed ID: 29664959
    [Abstract] [Full Text] [Related]

  • 5. Pulmonary arterial capacitance in children with idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease: relation to pulmonary vascular resistance, exercise capacity, and survival.
    Sajan I, Manlhiot C, Reyes J, McCrindle BW, Humpl T, Friedberg MK.
    Am Heart J; 2011 Sep 01; 162(3):562-8. PubMed ID: 21884877
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep 01; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 8. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies.
    D'Alto M, Diller GP.
    Heart; 2014 Sep 01; 100(17):1322-8. PubMed ID: 24829371
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension.
    Douwes JM, Roofthooft MT, Bartelds B, Talsma MD, Hillege HL, Berger RM.
    Int J Cardiol; 2013 Sep 30; 168(2):1370-7. PubMed ID: 23340486
    [Abstract] [Full Text] [Related]

  • 12. C-reactive protein in adults with pulmonary arterial hypertension associated with congenital heart disease and its prognostic value.
    Scognamiglio G, Kempny A, Price LC, Alonso-Gonzalez R, Marino P, Swan L, D' Alto M, Hooper J, Gatzoulis MA, Dimopoulos K, Wort SJ.
    Heart; 2014 Sep 30; 100(17):1335-41. PubMed ID: 24790070
    [Abstract] [Full Text] [Related]

  • 13. Congenital heart disease-associated pulmonary arterial hypertension: preliminary results from a novel registry.
    Rose ML, Strange G, King I, Arnup S, Vidmar S, O'Donnell C, Kermeen F, Grigg L, Weintraub RG, Celermajer DS.
    Intern Med J; 2012 Aug 30; 42(8):874-9. PubMed ID: 22212153
    [Abstract] [Full Text] [Related]

  • 14. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005.
    van Loon RL, Roofthooft MT, Hillege HL, ten Harkel AD, van Osch-Gevers M, Delhaas T, Kapusta L, Strengers JL, Rammeloo L, Clur SA, Mulder BJ, Berger RM.
    Circulation; 2011 Oct 18; 124(16):1755-64. PubMed ID: 21947294
    [Abstract] [Full Text] [Related]

  • 15. Contemporary survival outcomes of congenital systemic-to-pulmonary shunt in children with borderline pulmonary vascular resistant index compared to Eisenmenger syndrome.
    Chaiwangyen N, Vijarnsorn C, Chungsomprasong P, Chanthong P, Kanjanauthai S, Thammasate P, Pacharapakornpong T, Bositthipichet D, Sengsim J, Soongswang J, Tocharoenchok T, Nitiyarom E, Tantiwongkosri K, Subtaweesin T, Durongpisitkul K.
    Sci Rep; 2024 Jul 23; 14(1):16867. PubMed ID: 39043775
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy.
    D'Alto M, Romeo E, Argiento P, Santoro G, Sarubbi B, Gaio G, Mélot C, Russo MG, Naeije R, Calabrò R.
    Heart; 2010 Sep 23; 96(18):1475-9. PubMed ID: 20668108
    [Abstract] [Full Text] [Related]

  • 18. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K, Jakrapanichakul D, Sompradikul S.
    J Med Assoc Thai; 2008 Feb 23; 91(2):196-202. PubMed ID: 18389984
    [Abstract] [Full Text] [Related]

  • 19. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
    Kermeen FD, Franks C, O'Brien K, Seale H, Hall K, McNeil K, Radford D.
    Heart Lung Circ; 2010 Oct 23; 19(10):595-600. PubMed ID: 20728407
    [Abstract] [Full Text] [Related]

  • 20. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV.
    Eur J Clin Invest; 2006 Sep 23; 36 Suppl 3():10-5. PubMed ID: 16919005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.